Abstract
Overestimating the Effects of Healthy Aging
Highlights
University of the Basque Country (UPV/EHU), Vitoria & IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Keywords: cognitive aging, Alzheimer’s disease, biomarkers, amyloidosis, neurodegeneration, neuroimaging
Since amyloid-β neuritic plaques and neurofibrillary tangles have been established as the pathological hallmarks of Alzheimer’s disease (AD), biomarkers of amyloidosis and neurodegeneration are used as in vivo indicators of the presence of Alzheimer’s pathology (Dubois et al, 2007, 2010; Sperling et al, 2011; Jack and Holtzman, 2013)
Two additional stages have been added to this model: stage 0, which represents cognitively intact people without brain amyloidosis, neurodegeneration, or subtle cognitive changes, and suspected non-amyloid pathology (SNAP), which is characterized by normal amyloid markers and abnormal neurodegeneration markers and which is not necessarily related to AD (Jack et al, 2012)
Summary
University of the Basque Country (UPV/EHU), Vitoria & IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Keywords: cognitive aging, Alzheimer’s disease, biomarkers, amyloidosis, neurodegeneration, neuroimaging. Recent modifications of the research and diagnostic criteria for AD reflect this trend by including cognitively normal (CN) at-risk-for-AD persons as a preclinical stage in the AD continuum (Dubois et al, 2007, 2010; Sperling et al, 2011).
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call